史上超全肿瘤分子靶向药名及对应靶点清单

2021-10-25 网络网络

很全，值得收藏！

肿瘤分子靶向药物利用肿瘤细胞与正常细胞之间分子生物学上的差异，抑制肿瘤细胞的生长增殖，最后使其死亡。肿瘤分子靶向治疗将比化疗更为有效、副作用更小，是非常有希望的一种肿瘤治疗方法。

近几年，国家花大力气解决老百姓的需求，高度重视抗癌靶向药的保障情况，力争在最短时间内让患者用的起药。近两年，NMPA相关机构加快了审批进程，加快获批FDA认证的药物，让更多的患者有药可用！另一方面，中国抗肿瘤新药研发快速发展，从仿制向原研创新转变，中国告别无药时代。2021抗癌新药井喷，国内有很多款抗癌新疗法获批上市。

为此，小编特意整理最新获批的肿瘤靶向药物，按癌种分类列表，方便实用，记得收藏！

注：所有表格中（红色表示尚未在中国内地尚未上市，#表示上市未批准治疗此种癌症，黑色粗体表示在中国内地新上市，黑色粗体斜体表示国产新药）。

一、肺癌

二、乳腺癌

三、结直肠癌

四、胃癌食管癌

五、肝胆胰腺癌

六、生殖系统肿瘤

七、泌尿系统肿瘤

八、血液系统肿瘤

九、头颈部癌

十、皮肤软组织肿瘤

十一、其他肿瘤

十二、不限癌种的靶向药

参考来源：

https://www.cn-healthcare.com/articlewm/202107 02/content-1239086.html.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1986946, encodeId=323819869467c, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jul 23 14:32:49 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078082, encodeId=c35920e808283, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 26 11:32:49 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064958, encodeId=b57d106495857, content=强，有用，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05a35653268, createdName=ms4000001922302083, createdTime=Fri Oct 29 12:54:51 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063756, encodeId=7a761063e5697, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d785442816, createdName=ms8000000545763740, createdTime=Mon Oct 25 13:53:02 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063753, encodeId=5e7e1063e53db, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Oct 25 13:46:58 CST 2021, time=2021-10-25, status=1, ipAttribution=)]
2022-07-23 yyanpro@21cn.c

#分子靶向#

111 0
[GetPortalCommentsPageByObjectIdResponse(id=1986946, encodeId=323819869467c, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jul 23 14:32:49 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078082, encodeId=c35920e808283, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 26 11:32:49 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064958, encodeId=b57d106495857, content=强，有用，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05a35653268, createdName=ms4000001922302083, createdTime=Fri Oct 29 12:54:51 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063756, encodeId=7a761063e5697, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d785442816, createdName=ms8000000545763740, createdTime=Mon Oct 25 13:53:02 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063753, encodeId=5e7e1063e53db, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Oct 25 13:46:58 CST 2021, time=2021-10-25, status=1, ipAttribution=)]
2022-03-26 howi

#肿瘤分子#

96 0
[GetPortalCommentsPageByObjectIdResponse(id=1986946, encodeId=323819869467c, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jul 23 14:32:49 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078082, encodeId=c35920e808283, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 26 11:32:49 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064958, encodeId=b57d106495857, content=强，有用，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05a35653268, createdName=ms4000001922302083, createdTime=Fri Oct 29 12:54:51 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063756, encodeId=7a761063e5697, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d785442816, createdName=ms8000000545763740, createdTime=Mon Oct 25 13:53:02 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063753, encodeId=5e7e1063e53db, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Oct 25 13:46:58 CST 2021, time=2021-10-25, status=1, ipAttribution=)]
2021-10-29 ms4000001922302083

强，有用，谢谢

115 0
[GetPortalCommentsPageByObjectIdResponse(id=1986946, encodeId=323819869467c, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jul 23 14:32:49 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078082, encodeId=c35920e808283, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 26 11:32:49 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064958, encodeId=b57d106495857, content=强，有用，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05a35653268, createdName=ms4000001922302083, createdTime=Fri Oct 29 12:54:51 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063756, encodeId=7a761063e5697, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d785442816, createdName=ms8000000545763740, createdTime=Mon Oct 25 13:53:02 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063753, encodeId=5e7e1063e53db, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Oct 25 13:46:58 CST 2021, time=2021-10-25, status=1, ipAttribution=)]
2021-10-25 ms8000000545763740

学习了

117 0
[GetPortalCommentsPageByObjectIdResponse(id=1986946, encodeId=323819869467c, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jul 23 14:32:49 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078082, encodeId=c35920e808283, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 26 11:32:49 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064958, encodeId=b57d106495857, content=强，有用，谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05a35653268, createdName=ms4000001922302083, createdTime=Fri Oct 29 12:54:51 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063756, encodeId=7a761063e5697, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d785442816, createdName=ms8000000545763740, createdTime=Mon Oct 25 13:53:02 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063753, encodeId=5e7e1063e53db, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Mon Oct 25 13:46:58 CST 2021, time=2021-10-25, status=1, ipAttribution=)]
2021-10-25 医鸣惊人

认真学习了。

118 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

史上超全肿瘤分子靶向药名及对应靶点清单

相关资讯

科室

工具

服务